Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
104 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR JUDITH TOTO-ROSAN
BATIMENT D SCM MEDICALE TOTO ZAC DE LA PROVIDENCE RETAIL PARK, 97139 LES ABYMES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Outre-mer La 1ère · 20/01/2023
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxObUVjckpwczNNbWREOVB0djR4ZTlYZ283UkQ2UnNraXZoanFYa3lVU1oxbThzZEZZMHlOaXpubjY5cmgwQ0dnNlhfVjBXQWkzVWlaVmhKMHc2MEh3Vkk2YWtrTEk1S0piYm9qRnRZbTRaTW9UOTlwbHVCV0NzaE5UUER1Sm0xRmY1R21sU3BHOXBhcGZ6Z0gzZ1JkUnp3R3VEZThYUQ?oc=5" target="_blank">L'épi
The Pan African medical journal · 2020
PloS one · 2021
Background The COVID-19 pandemic has brought to light the lacunae in the preparedness of healthcare systems across the globe. This preparedness also includes the safety of healthcare providers (HCPs) at various levels. Sudden spread of COVID-19 infection has created threatening and vulnerable conditions for the HCPs. The current pandemic situation has not only affected physical health of HCPs but also their mental health. Objective This study aims to understand the prevalence and severity of secondary traumatic stress, optimism parameters, along with states of mood experienced by the HCPs, viz., doctors, nurses and allied healthcare professionals (including Physiotherapist, Lab technicians, Phlebotomist, dieticians, administrative staff and clinical pharmacist), during the COVID-19 lockdown in India. Methodology The assessment of level of secondary traumatic stress (STS), optimism/pessimism (via Life Orientation Test-Revised) and current mood states experienced by Indian HCPs in the present COVID-19 pandemic situation was done using a primary data of 2,008 HCPs from India during the first lockdown during April-May 2020. Data was collected through snow-ball sampling technique, reaching out to various medical health care professionals through social media platforms. Result Amongst the study sample 88.2% of doctors, 79.2 of nurses and 58.6% of allied HCPs were found to have STS in varying severity. There was a female preponderance in the category of Severe STS. Higher optimism on the LOTR scale was observed among doctors at 39.3% followed by nurses at 26.7% and allied health care professionals 22.8%. The mood visual analogue scale which measures the “mood” during the survey indicated moderate mood states without any gender bias in the study sample. Conclusion The current investigation sheds light on the magnitude of the STSS experienced by the HCPs in the Indian Subcontinent during the pandemic. This hitherto undiagnosed and unaddressed issue, calls for a dire need of creating better and accessible mental health programmes and facilities for the health care providers in India.
Health science reports · 2024
AbstractBackgroundIn this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line treatment potentiated the objective response rate.Patients/MethodsA multicentre, randomized, open label, phase‐II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel‐curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time‐to‐progression, progression‐free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy.ResultsIn this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time‐to‐progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression‐free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance (p = 0.14).ConclusionIn this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second‐line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diabetic medicine : a journal of the British Diabetic Association · 2026 · Journal Article
Zhu X, Lee ES, Chan FHF, Yin R, et al.
Infection and drug resistance · 2025 · Journal Article
Isidore KK, Michael Paterne MN, Judith BK, Jean KK, et al.
Drug metabolism and disposition: the biological fate of chemicals · 2025 · Journal Article
Justine B, Helen G, Felix H, Birk P, et al.
Cureus · 2025 · Journal Article
J N, Gunabooshanam B, Balasubramanian S
Current molecular medicine · 2024 · Journal Article
Jayashree P, Kalpita M, Judith T, Singh AS, et al.
Cureus · 2021 · Journal Article
Vellingiri K, Ethiraj P, S NJ, Shanthappa AH, et al.
The Pan African medical journal · 2020 · Journal Article
Diengou NH, Cumber SN, Nkfusai CN, Mbinyui MS, et al.
Preventive medicine reports · 2019 · Journal Article
Jacqueline W, Marie-Therese P, Judith T, Johannes P, et al.
Neurological research · 2023 · Journal Article
Gisela Z, Carla P, Josefina B, Tomas I, et al.
PloS one · 2021 · Journal Article
K N M, Parashar N, Kumar CRS, Verma V, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020 · Published Erratum
Ricardo A, Cecilia Q, Bárbara E, Leila C, et al.
Seizure · 2025 · Journal Article
Annalise W, Anita H, Judith D, Sereena R, et al.
Health economics review · 2025 · Journal Article
Shobha V, Singhai S, Haridas V, V S, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.
Health science reports · 2024 · Journal Article
Judith PJ, Maureen B, Mélanie P, Fabrice K, et al.
Cureus · 2024 · Journal Article
Kg G, J R
Seizure · 2025 · Journal Article
Annalise W, Anita H, Judith D, Sereena R, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.
BMC health services research · 2025 · Journal Article
Elodie R, Leila R, Judith MF, Linda C, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Chandwani A, J S, Dwivedi A, Sivasami K, et al.
BMC public health · 2026 · Journal Article
Judith II, David EI, Jonah OE, Ikenna UC
BMC public health · 2026 · Journal Article
Judith II, David EI, Jonah OE, Ikenna UC
Cureus · 2025 · Case Reports
K R, J P, R R, B V MM, et al.
Cureus · 2023 · Journal Article
J S, S L, Nair MV, R KT, et al.
Cureus · 2023 · Case Reports
J SK, Waheed MD, Batool S, Holder SS, et al.